Skip to main content
SpringerLink
Log in

Understanding use of bevacizumab for newly diagnosed ovarian cancer in the US before FDA approval

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Jorge S, et al. Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States. JCO Oncology Practice : OP2000918, 12 Apr 2021. Available from: URL: http://doi.org/10.1200/OP.20.00918

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Understanding use of bevacizumab for newly diagnosed ovarian cancer in the US before FDA approval. PharmacoEcon Outcomes News 877, 25 (2021). https://doi.org/10.1007/s40274-021-7674-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7674-3

Search

Navigation